Next Article in Journal
Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer
Previous Article in Journal
Identification of Genetic Variants for Risk Prediction and Early Diagnosis of Age-Related Macular Degeneration in the Taiwanese Population
Previous Article in Special Issue
NCOA7 Regulates Growth and Metastasis of Clear Cell Renal Cell Carcinoma via MAPK/ERK Signaling Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 6
10.3390/ijms25063231
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Transcription Factor MYB as Therapeutic Target: Current Developments

by
Karl-Heinz Klempnauer
Institute for Biochemistry, University of Münster, 48149 Münster, Germany
Int. J. Mol. Sci. 2024, 25(6), 3231; https://doi.org/10.3390/ijms25063231
Submission received: 28 January 2024 / Revised: 27 February 2024 / Accepted: 6 March 2024 / Published: 12 March 2024
(This article belongs to the Special Issue Advanced Biochemical Research: Transcription in Cancer Initiation and Progression)
Browse Figures
Versions Notes

Abstract

The MYB protein is a pivotal player in the cellular transcriptional network, influencing major important processes such as cell proliferation, differentiation, and apoptosis. Because of its role in oncogenesis, MYB is now a compelling target for therapeutic interventions in cancer research. This review summarizes its molecular functions and current therapeutic approaches aiming to inhibit its oncogenic activity.
Keywords: MYB; inhibitor; AML; leukemia; adenoid cystic carcinoma; transcription; p300; gene expression MYB; inhibitor; AML; leukemia; adenoid cystic carcinoma; transcription; p300; gene expression

Share and Cite

MDPI and ACS Style

Klempnauer, K.-H. Transcription Factor MYB as Therapeutic Target: Current Developments. Int. J. Mol. Sci. 2024, 25, 3231. https://doi.org/10.3390/ijms25063231

AMA Style

Klempnauer K-H. Transcription Factor MYB as Therapeutic Target: Current Developments. International Journal of Molecular Sciences. 2024; 25(6):3231. https://doi.org/10.3390/ijms25063231

Chicago/Turabian Style

Klempnauer, Karl-Heinz. 2024. "Transcription Factor MYB as Therapeutic Target: Current Developments" International Journal of Molecular Sciences 25, no. 6: 3231. https://doi.org/10.3390/ijms25063231

APA Style

Klempnauer, K.-H. (2024). Transcription Factor MYB as Therapeutic Target: Current Developments. International Journal of Molecular Sciences, 25(6), 3231. https://doi.org/10.3390/ijms25063231

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop